|1.||Ahmed, Niaz: 25 articles (12/2015 - 01/2007)|
|2.||Wahlgren, Nils: 23 articles (12/2015 - 01/2007)|
|3.||Lees, Kennedy R: 17 articles (12/2015 - 01/2007)|
|4.||Toni, Danilo: 11 articles (12/2015 - 01/2007)|
|5.||Mikulik, Robert: 10 articles (12/2015 - 09/2010)|
|6.||Ford, Gary A: 9 articles (01/2015 - 01/2007)|
|7.||Ahmed, N: 8 articles (01/2014 - 11/2008)|
|8.||Dávalos, Antoni: 7 articles (09/2010 - 01/2007)|
|9.||Kobayashi, Adam: 6 articles (09/2015 - 09/2006)|
|10.||Kaste, Markku: 6 articles (11/2014 - 01/2007)|
03/01/2011 - "The SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) and SITS-ISTR (Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register) registries evaluated the safety and efficacy of tPA at both 3 and 4.5 hours and showed promising results. "
10/01/2010 - "The aim of this study is to compare the safety and efficacy of thrombolysis in the Polish SITS-ISTR stroke patient population with patients registered in SITS-MOST. "
11/01/2008 - "SITS-MOST was embedded within the Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR), an internet-based, international monitoring registry for auditing the safety and efficacy of routine therapeutic use of thrombolysis in acute ischaemic stroke. "
03/20/2012 - "To assess safety and efficacy of thrombolysis in 18- to 50-year-old patients compared to those aged 51 to 80 years recorded in the Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). "
06/01/2009 - "The SITS-ISTR (Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register) is a register to evaluate the safety and efficacy of routine use of thrombolysis in acute ischemic stroke. "
02/01/2010 - "First, the findings suggested that despite anaemia and transfusion being ubiquitous in this cancer setting, it sits low in the hierarchy of clinical concerns (The unimportance of anaemia). "
08/01/2000 - "In the mean follow-up period of 7.5 years (range 11 months-15.8 years), no recurrence of tumor was observed on magnetic resonance images, whereas recurrence of SITS was found in two patients with no tumor regrowth. "
08/01/2000 - "In the other two patients, SITS persisted because of tumor rests in the cavernous sinus. "
12/01/1995 - "Interestingly, in all tumors that we investigated, the breakpoints occurred at sits of two or three nucleotide matches between the contributing germline sequences. "
10/01/1976 - "The kinetics of irreversible inhibition is best explained by the irreversible binding of SITS to the sulfate transport site, and therefore makes SITS a potentially useful probe for the quantiation of these sites in the tumor cell. "
08/01/2014 - "The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST."
06/01/2012 - "The SITS SICH risk score predicts large cerebral parenchymal hemorrhages associated with severe clinical deterioration. "
06/01/2010 - "A slight, non-significant, increase of symptomatic intracerebral hemorrhage (SICH) as per SITS protocol was observed (2.4 vs. 1.6%, p = 0.15). "
12/01/2008 - "The adjusted proportion of symptomatic intracerebral hemorrhage for SITS-MOST was 8.5% (95% CI, 7.9 to 9.0) versus 8.6% (6.3 to 11.6) for pooled RCTs; mortality was 15.5% (14.7 to 16.2) versus 17.3% (14.1 to 21.1); and independency was 50.4% (49.6 to 51.2) versus 50.1% (44.5 to 54.7), respectively. "
06/01/2010 - "We compared the baseline characteristics, treatment delay, rate of symptomatic intracerebral hemorrhage and functional outcome at 90 days after treatment between patients enrolled in centres in Belgium and the non-Belgian SITS-registry population. "
06/06/1983 - "SITS, an inhibitor of anion exchange, was found to be a potent and selective inhibitor of L-glutamic acid uptake by cultured LRM55 glioma cells and rat brain astrocytes. "
01/01/2014 - "Given that CREB sits at the hub of key cancer cell signalling pathways, understanding the role of glioma-specific CREB function may lead to improved novel combinatorial anti-tumour therapies, which can complement existing PI3K-specific drugs undergoing early phase clinical trials. "
08/01/2000 - "In addition, coexistent primary hyperthyroidism was found in two other patients despite remission of SITS after surgery. "
08/01/2000 - "In addition, even satisfactory resection of the tumor sometimes results in recurrence of SITS or hyperthyroid symptoms due to coexistent primary hyperthyroidism. "
|1.||Tissue Plasminogen Activator (Alteplase)
|2.||Complement System Proteins (Complement)
|5.||Blood Glucose (Blood Sugar)
|9.||Silicon Dioxide (Sand)
|3.||Surgical Instruments (Clip)